Ponesimod
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Ponesimod. Ponesimod is a selective sphingosine-1-phosphate receptor (S1PR) modulator. Fully referenced neurology checklist.
Mechanism
- Ponesimod is a selective sphingosine-1-phosphate receptor (S1PR) modulator
- It sequesters lymphocytes in lymphoid organs
- Its effect is rapidly reversible on discontinuation
Dose
Locked: subscribe to see this section.
Cardiorespiratory side effects
Locked: subscribe to see this section.
Neurological side effects
Locked: subscribe to see this section.
Systemic effects
Locked: subscribe to see this section.
Infectious side effects
Locked: subscribe to see this section.
Laboratory side effects
Locked: subscribe to see this section.
Infection screen
Locked: subscribe to see this section.
Monitoring investigations
Locked: subscribe to see this section.
Other investigations
Locked: subscribe to see this section.
Indications to discontinue treatment
Locked: subscribe to see this section.
References
- D'Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis 2016; 7:18-33.
- Olsson T, Boster A, Fernández Ó, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. JNNP 2014; 85:1198-208.
- Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol 2021; 78:558-567.
- Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 2021; 14:17562864211039648.
